Company news

AnaptysBio, Inc. news in 2025

AnaptysBio, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis

December 15, 2025

Anaptys Announces Participation in December Investor Conferences

November 24, 2025

Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary

November 20, 2025

Anaptys Announces $100 Million Stock Repurchase Plan

November 20, 2025

Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis

November 9, 2025

Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update

November 3, 2025

Anaptys Announces Participation in November Investor Conferences

November 3, 2025

Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation

October 28, 2025

Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025

October 12, 2025

Anaptys to Provide Overview of ANB033, a CD122 antagonist, at Virtual Investor Event on Tuesday, Oct. 14

September 28, 2025

Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026

September 28, 2025

Anaptys Announces Participation in September Investor Conferences

August 26, 2025

Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update

August 5, 2025

Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA

June 2, 2025

Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025

May 26, 2025

Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update

May 4, 2025

Anaptys Announces Stock Repurchase Plan

March 23, 2025

Anaptys Announces Participation in March Investor Conferences

February 26, 2025

Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

February 26, 2025

Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months

February 11, 2025

Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025

February 10, 2025

Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist

February 2, 2025

Anaptys to Present at the Guggenheim SMID Cap Biotech Conference

February 2, 2025

Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 6, 2025

Decks in 2025